<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628974</url>
  </required_header>
  <id_info>
    <org_study_id>20-413</org_study_id>
    <nct_id>NCT05628974</nct_id>
  </id_info>
  <brief_title>Normal Donor Blood Draws for Platelet Studies and Biomarker Evaluation (ND-PLT)</brief_title>
  <acronym>ND-PLT</acronym>
  <official_title>Normal Donor Blood Draws for Platelet Studies and Biomarker Evaluation (ND-PLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center study at the Cleveland Clinic Main Campus designed to study&#xD;
      biomarkers in healthy individuals to identify novel mechanisms of platelet activation and how&#xD;
      platelets drive vascular inflammation and thrombosis in diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our past studies have discovered novel platelet activation pathways that may be targets of&#xD;
      therapeutic development. We have also defined an important role for a shift in platelet&#xD;
      phenotype in vascular disease. Our studies use both in vivo animal models and validation&#xD;
      using human platelets from isolated blood. Platelets from healthy individuals may be compared&#xD;
      to patients with vascular diseases in the IRB approved protocol &quot;Vascular Lab Resource&quot; (IRB&#xD;
      #19-1451) study which is actively recruiting patients at the Cleveland Clinic Main Campus and&#xD;
      studies patients with vascular diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To collect blood samples</measure>
    <time_frame>10 years</time_frame>
    <description>To establish a biorepository for normal healthy cohort of subjects</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Healthy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Voluntary donors will be screened by questioning for use of anti-coagulant medications such&#xD;
        as aspirin or other non-steroidal anti-inflammatory agents, in the past 10 days, or for&#xD;
        hematopoietic diseases. Only healthy volunteers included as platelet donors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 to 65 years old&#xD;
&#xD;
          -  Healthy Male &amp; Female voluntary participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who have taken anticoagulant or antiplatelet medications in past 10 days&#xD;
&#xD;
          -  Individuals with hematopoetic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Scott Cameron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Cameron, MD, PhD</last_name>
    <phone>216-444-1680</phone>
    <email>cameros3@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Cameron, MD, PhD</last_name>
      <phone>216-444-1680</phone>
      <email>cameros3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Rohan Bhandari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Godwin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cameron SJ, Ture SK, Mickelsen D, Chakrabarti E, Modjeski KL, McNitt S, Seaberry M, Field DJ, Le NT, Abe J, Morrell CN. Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion. Circulation. 2015 Jul 7;132(1):47-58. doi: 10.1161/CIRCULATIONAHA.115.015656. Epub 2015 May 1.</citation>
    <PMID>25934838</PMID>
  </reference>
  <reference>
    <citation>Schmidt RA, Morrell CN, Ling FS, Simlote P, Fernandez G, Rich DQ, Adler D, Gervase J, Cameron SJ. The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction. Transl Res. 2018 May;195:1-12. doi: 10.1016/j.trsl.2017.11.006. Epub 2017 Dec 2.</citation>
    <PMID>29274308</PMID>
  </reference>
  <reference>
    <citation>Hilt ZT, Pariser DN, Ture SK, Mohan A, Quijada P, Asante AA, Cameron SJ, Sterling JA, Merkel AR, Johanson AL, Jenkins JL, Small EM, McGrath KE, Palis J, Elliott MR, Morrell CN. Platelet-derived beta2M regulates monocyte inflammatory responses. JCI Insight. 2019 Mar 7;4(5):e122943. doi: 10.1172/jci.insight.122943. eCollection 2019 Mar 7.</citation>
    <PMID>30702442</PMID>
  </reference>
  <reference>
    <citation>Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997 Apr;77(4):748-54.</citation>
    <PMID>9134654</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Scott Cameron, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

